An increased risk of cardiotoxicity, especially LVEF reduction (5–11%), hypertension (11–30%), or QT prolongation (0–5%), was highlighted with BRAF and MEK inhibitors treatment [115]. This evidence concerns the gene BRAF and Hypertension.